The role of cetuximab in the treatment of squamous cell cancer of the head and neck

Bibliography

• JEMAL A, MURRAY T, WARD E et aL: Cancer Statistics, 2005. CA Cancer J. Clin. (2005) 55:10–30.
   PubMed Web of Science ®Google Scholar
• DE BONO JS, ROWINSKY EK: The ErbB receptor family: a therapeutic target for cancer. Trends Mot Med. (2002) 8(4 Suppl.):519.
   Google Scholar
• ULLRICH A, SCHLESSINGER J: Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61:203–212.
   PubMed Web of Science ®Google Scholar
• LEMMON MA, BU Z, LADBURY JE et al.: Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. (1997) 16:281–294.
   PubMed Web of Science ®Google Scholar
• GIBSON S, TU S, OYER R et ed.: Epidermal growth factor receptor protects epithelial cells against Fas-induced apoptosis. J. Biol. Chem. (1999) 272:17612–17618.
   Google Scholar
• MATTOON D, KLEIN P, LEMMON MA, LAX I, SCHLESSINGER J: The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc. Natl. Acad. Sci. USA (2004) 101(4):923–928.
   PubMed Web of Science ®Google Scholar
• KIMMIG R, PFEIFFER D, LANDSMANN H, HEPP H: Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: evidence for down-regulation in cervical cancer. Int. J. Cancer (Pred. OncoL) (1997) 74:365–373.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, TWEARDY DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. (1993) 53:3579–3584.
   PubMed Web of Science ®Google Scholar
• DASSONVILLE O, FORMENTO JL, FRANCOUL M et al.: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol. (1993) 11:1873–1878.
   PubMed Web of Science ®Google Scholar
• RUBIN GRANDIS J, MELHEM MF, GOODING WE et al.: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. (1998) 90:824–832.
   PubMed Web of Science ®Google Scholar
• LEE JW, SOUNG YH, KIM SY et ed.: Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. (2005) 11:2879–2882.
   Google Scholar
• LI S, SCHMITZ KR, JEFFREY PD et al.:Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 7:301–311.
   PubMed Web of Science ®Google Scholar
• GILL GN, KAWAMOTO T, COCHET C et al.: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. (1984) 259:7755–7760.
   PubMed Web of Science ®Google Scholar
• SATO JD, KAWAMOTO T, LE AD et aL: Biological effect in vitro of monoclonal antibodies to human EGF receptors. Mot Biol. Med. (1983) 1:511–529.
   Google Scholar
• FAN Z, MAUI H, ALTAS I et aL: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti- epidermal growth factor receptor monoclonal antibodies. Cancer Res. (1993) 53:4322–4328.
   PubMed Web of Science ®Google Scholar
• WU X, RUBIN M, FAN Z et al.: Involvement of p27kipl in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 12:1397–1403.
   PubMed Web of Science ®Google Scholar
• FAN Z, LU Y, WU X et al.: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. (1994) 269:27595–27602.
   PubMed Web of Science ®Google Scholar
• BASELGA J, NORTON L, MASUI H et al.: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor antibodies. J. Natl. Cancer Inst. (1993) 85:1327–1333.
   PubMed Web of Science ®Google Scholar
• BANCROFT CC, CHEN Z, YEH J et aL: Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int. J. Cancer (2002) 99:538–548.
   PubMed Web of Science ®Google Scholar
• KUMAR R, ADAM L, MANDAL M et aL: Anti-invasive action of anti-EGF receptor antibody C225: suppression of focal-adhesion kinase/B-catenin signaling components. Proc. Am. Assoc. Cancer Res. (2002) 43:Abstract 2879.
   Google Scholar
• HUANG SM, LI J, HARARI PM: Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. MoL Cancer Ther. (2002) 1:507–514.
   PubMed Web of Science ®Google Scholar
• ABOUD-PIRAK E, HURWITZ E, PIRAK ME et al.: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. NatL Cancer Inst. (1988) 80:1605–1611.
   Google Scholar
• FAN Z, BASELGA J, MASUI H et al.: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. (1993) 53:4637–4642.
   PubMed Web of Science ®Google Scholar
• MATAR P, ROJO F, CASSIA R et aL: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. (2004) 10:6487–6501.
   PubMed Web of Science ®Google Scholar
• HUANG S, ARMSTRONG EA, BENAVENTE S et al.: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. (2004) 64:5355–5362.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, BIANCO R, DAMIANO Vet al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. (2000) 6:3739–3747.
   Google Scholar
• HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 59:1935–1940.
   PubMed Web of Science ®Google Scholar
• NASU S, ANG KK, FAN Z et al.: C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(2):474.
   PubMed Web of Science ®Google Scholar
• BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor chimeric antibody C225 alone and in combination with cisplatin. Clin. Oncol. (2000) 18(4):904–914.
   Web of Science ®Google Scholar
• RUBIN EH, DOROSHOW J, HIDALGO M et aL: A study to assess the pharmacokineteics (PK) of a single infusion of cetuximab (IMC-C225). Proc. Am. Soc. Clin. Oncol. (2004) 22:216s (abstract 3084).
   Google Scholar
• SHIN DM, DONATO NJ, PEREZ-SOLER R et al.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. (2001) 7:1204–1213.
   PubMed Web of Science ®Google Scholar
• HERBST RS, ARQUETTE M, SHIN DM et al.: Epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck: a Phase II, multicenter study. J. Clin. Oncol. (2005) 23:(In Press).
   Google Scholar
• BASELGA J, TRIGO JM, BOURHIS J et al.: A Phase II multicenter study of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. (2005) 23:(In Press).
   Google Scholar
• CHAN ATC, HSU MM, GOH BC et aL: A Phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2000.
   Google Scholar
• BURTNESS BA, LI Y, FLOOD W et ed:Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proceedings of the AACR/ NCl/EORTC International Conference on Molecular Targets in Cancer Therapy (2003):Abstract 77.
   Google Scholar
• TRIGO J: Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. Proc. Am. Soc. Clin. Oncol (2004) 23:487.
   Google Scholar
• BONNER JA, GIRALT J, HARARI PM et al.: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carccinoma of head and neck: a Phase III study of high dose radiation with or without cetuximab. Proc. Am. Soc. Clin. Oncol (2004) 22:489 (Late-Breaking Abstract).
   Google Scholar
• PFISTER DG, ALIFF TB, KRAUS DH et al.: Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): preliminary evaluation of a new combined-modality paradigm. Proc. Am. Soc. Clin. Oncol. (2003) 22:495 (abstract 1993).
   Google Scholar
• CHUNG KY SHIA J, KEMENY NE et ell.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol (2005) 23:1803–1810.
   Google Scholar
• PSYRRI A, YU Z, WEINBERGER PM et al.: Analysis of the epidermal growth factor signalling pathway in head and neck cancer patients in vivo. Clin. Cancer Res. (2005) (In Press).
   Google Scholar
• MORONI M, VERONESE S, BEN VENUTI S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. (2005) 6:279–286.
   Google Scholar
• COHEN EE, ROSEN F, STADLER WM et al.: Phase II trial of ZD1839 in recurrent of metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2003) 21:1980–1987.
   PubMed Web of Science ®Google Scholar
• KANE MA, COHEN E, LIST M et al.: Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol. (2004) 22:509s (abstract 5580.
   Google Scholar
• SOULIERES D, SENZER NN, VOKES EE et al.: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol (2004) 22:77–85.
   PubMed Web of Science ®Google Scholar
• ADELSTEIN DJ, YI LI, GEORGE Let al.: An Intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol (2003) 21:92–98.
   Google Scholar
• OGISO H, ISHITANI R, NUREKI O et al.: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 110(6):775–787.
   PubMed Web of Science ®Google Scholar
• BONNER JA, GIRALT J, HARARI PM et al.: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. j Clin. Oncol (2004) 22\(Suppl. 14):489s.
   Google Scholar